Brucella abortus S19Δ per vaccine
A Technology License Agreement (TLA) ceremony on “Brucella abortus S19Δ per vaccine” developed by ICAR-Indian Veterinary Research Institute (IVRI) was held recently.
- Brucellosis is one of the most important zoonotic diseases worldwide and also endemic in India causing huge economic losses to dairy industry due to infertility, abortion, birth of weak offsprings and reduced productivity.
- Brucellosis is a bacterial infection that affects thousands of people worldwide. Avoiding unpasteurised dairy products and taking precautions when working with animals or in a laboratory can help prevent brucellosis.
- Symptoms may include joint and muscle pain, fever, weight loss and fatigue. Some people develop stomach pain and cough.
About the vaccine
- In India, calf-hood vaccination is practiced using live attenuated B. abortus S19 strain for control of the disease.
- B. abortus S19 strain is a very strong immunogen and provides lifelong immunity. However, this vaccine strain has several drawbacks like – residual virulence to human and animals, not suitable for vaccination in adult animals, causes abortion when used in pregnant animals and also interferes with sero-diagnosis of clinical infection.
- To overcome some of these drawbacks, a modified strain of B. abortus S19 has been developed at ICAR-IVRI. The vaccine candidate was developed under Department of Biotechnology funded “Brucellosis network program”.
- In the process of modifying the S19 strain, lipopolysaccharide (LPS) structure of the organism was altered through deletion mutation. The newly developed strain was named as B. abortus S19Δper. Vaccine potential of S19Δper has been evaluated in experimental small animal model and also in buffalo calves.
- The vaccine has great demand in India and will be of immense help in the national control programme on brucellosis. The vaccine has DIVA capability meaning that it can differentiate between naturally infected and vaccinated animals.